Yesterday, Mekonos, a biotechnology company that is currently working on launching the groundbreaking system-on-a-chip (SoC) for targeted ex vivo gene engineering, announced that it had raised $4.6 million to accelerate their gene engineering platform for current and new commercial partnerships. The financing round was led by Novartis AG and input from institutional VCs.
The platform is a physically controlled infrastructure that enables researchers to treat therapy cells that can be controlled like data while removing statistical uncertainty. The core of the platform is a scalable gene-editing chip, which underlines a high innovative level which would have not been thinkable a couple of years ago.
With its platform, the company has achieved a breakthrough that allows for molecular delivery in gene editing and synthetic biology. It is scalable across all cell types and has shown to be a great solution for partners so far, helping them to increase capacity, increase discoveries, and develop new preclinical assets in the cell and gene therapy area.
Just in the past year, the biotech company had ensured collaborations with two top 5 pharma companies and cell therapy research groups for their high yield SoC molecular delivery. Mekonos also recently completed pilots with key top pharma companies and institutes that suggested high effectiveness of modified gene expression and cell viability. The goal now is to expand existing collaborations and find new partners to expand their research.
Partner with accredited companies
Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.
Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.
With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.
Still a little unsure? Check out what our customers have to say about us here.